Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmeriHealth specialty drug Prior Auth Policy Updat…
    Ask Trek AI about this page
    CurrentAmeriHealthPolicy N/A

    Specialty drugs requiring precertification

    Customize your policy alerts

    Sign up for all AmeriHealth policy alerts

    Know when AmeriHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    List of specialty drugs that require precertification for AmeriHealth Medicare Advantage members, effective January 1, 2026; applies to listed brands, generics, and biosimilars and affects providers submitting precertification requests.

    Policy Summary
    PayerAmeriHealth
    PolicySpecialty drugs requiring precertification
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain precertification for all listed specialty drugs and their generics or biosimilars prior to provision for AmeriHealth Medicare Advantage members.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+therapy categories listed
    5therapeutic categories in segment

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ~80
    individual agents (approx)
    Yesincludes biosimilars
    eviCoreexternal precert vendor

    Coverage Criteria

    The drug list excludes ophthalmological conditions for agents marked with §. Where a drug or class is annotated with §, the exclusion reads: except for ophthalmological conditions.

    Therapeutic Categories and Codes

    Pulmonary arterial hypertension agentsmixed
    FlolanFlolan ®
    RemodulinRemodulin ®
    RevatioRevatio ®
    TrevyentTrevyent*
    TyvasoTyvaso ®
    Uptravi IVUptravi IV
    VeletriVeletri ®
    VentavisVentavis ®
    No codes listed
    Respiratory agentsmixed
    CinqairCinqair ®
    depemokimabdepemokimab*
    OmlycloOmlyclo
    SynagisSynagis ®
    XolairXolair ®
    No codes listed
    Respiratory enzymes (Alpha-1 antitrypsin)mixed
    AralastAralast
    GlassiaGlassia™
    ProlastinProlastin ®
    ZemairaZemaira ®
    No codes listed
    Tumor-infiltrating lymphocyte (TIL) and T-cell therapiesmixed
    AmtagviAmtagvi™
    ImdelltraImdelltra™
    linvoseltamablinvoseltamab*
    TecelraTecelra ®
    No codes listed
    Miscellaneous therapeutic agentsmixed
    AdakveoAdakveo ®
    AmvuttraAmvuttra™
    apitegromabapitegromab*
    BkemvBkemv™
    CoselaCosela ®
    CrysvitaCrysvita
    deramiocelderamiocel*
    EnjaymoEnjaymo™
    EpibbliEpysqli ®
    EvkeezaEvkeeza™
    1–10 of 36
    1/4
    No codes listed

    Provider Actions and Authorization Requirements

    Prior Authorization

    Precertification required for listed specialty drugs

    As of January 1, 2026, all listed specialty brands and their generic equivalents or biosimilars require precertification for AmeriHealth Medicare Advantage members; the list is subject to change.

    • Applies to all brands listed in the document and any generics or biosimilars.
    Note

    Prior authorization details not specified in this list

    This segment lists drug names by therapeutic category and does not provide detailed prior authorization criteria or clinical triggers.

    • Providers must follow general precertification process but no PA rules are specified here.
    Note

    Background

    This document is a formulary/precertification listing of specialty drugs that require prior authorization for AmeriHealth Medicare Advantage members effective January 1, 2026. It groups drugs by therapeutic area and specifies that all listed brands, their generic equivalents, and FDA‑approved biosimilars within a class require precertification. Notes indicate certain products are pending approval, subject to external precertification review by CareCore National (eviCore), and that limitations, copayments, and annual benefit changes may apply.

    Definitions and Notes

    Biosimilars and generics
    ScopeAll listed brand drugs and their generic equivalents or biosimilars require precertification for AmeriHealth Medicare Advantage members effective January 1, 2026.
    Includes FDA‑approved biosimilarsPrecertification requirements apply to all FDA‑approved biosimilars to the reference products noted (‡).
    Classwide applicabilityAny drug that can be classified under the listed therapeutic class (including unlisted brand or generic names and new FDA approvals in that class during the benefit year) requires precertification.
    Ophthalmological exceptionEntries marked with § are excepted for ophthalmological conditions (i.e., § except for ophthalmological conditions).
    Contact for full listThis is not a complete list; for a complete listing call AmeriHealth Member Help Team or visit amerihealthmedicare.com.

    Step Therapy

    StepRequirement
    [{"text":"1","status":""},{"text":"No specific step-therapy sequences are provided in this document excerpt; class-level precertification applies to all drugs listed under a therapeutic class ("All drugs that can be classified under this header require precertification"), including unlisted brands, generics, and FDA‑approved biosimilars.","status":""}]

    Site of Care

    Note

    Site-of-care rules not specified for listed IV agents

    Site-of-care requirements (e.g., infusion center rules) are not specified in this portion of the document despite inclusion of intravenous agents.

    • If site-of-care rules are needed, consult the full policy or payer/vendor guidance.

    Biosimilar Notes

    Billing Rule

    Biosimilar applicability for products marked with ‡

    Precertification requirements apply to all FDA‑approved biosimilars to the reference products noted with ‡ in the list (e.g., Soliris ® is marked with ‡).

    • When a reference product is marked with ‡, any FDA‑approved biosimilar to that product also requires precertification.
    Policy Summary
    PayerAmeriHealth
    PolicySpecialty drugs requiring precertification
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain precertification for all listed specialty drugs and their generics or biosimilars prior to provision for AmeriHealth Medicare Advantage members.
    SourceLink
    On This Page
    Coverage CriteriaTherapeutic Categories and CodesProvider Actions and Authorization RequirementsBackgroundDefinitions and NotesStep TherapySite of CareBiosimilar Notes

    List subject to change; biosimilars and class members require precertification

    The list is subject to change; precertification requirements also apply to FDA‑approved biosimilars and to any unlisted brands, generics, or new drugs approved in a listed class during the benefit year.

    • Reference-product biosimilars marked with ‡ are included under the biosimilar applicability note.
    Note

    Drug list only — no extra provider actions in this segment

    This excerpt contains only drug listings by category (see respiratory and miscellaneous sections); no additional provider-action instructions are included in chunk 19 beyond the drug names.

    • Providers should not infer authorization criteria from the drug list alone.
    Documentation Required

    Precertification review vendor and documentation notes

    Drugs marked with † are subject to precertification review by CareCore National, LLC d/b/a eviCore healthcare; benefits, copayments, and restrictions may apply and may change annually.

    • Contact the external review vendor for precertification requirements where noted.
    • Benefits and cost‑sharing provisions may change on January 1 of each year.
    Note

    Agent listing only — no additional provider instructions in this section

    The miscellaneous therapeutic agents section lists many brands but does not specify additional provider-action steps or documentation requirements in chunk 22 itself.

    • Providers must submit precertification requests when applicable, but chunk 22 contains only the agent names.
    Denial Risk

    Denial risk if precertification is not obtained

    Failure to obtain precertification for any listed specialty drug, including its generic equivalents or biosimilars, may result in denial or coverage limitation.

    • Obtain precertification before initiating therapy to avoid claim denials or coverage actions.
    Note

    No authorization/denial triggers provided in this list

    This segment provides only drug names grouped by category and does not include explicit authorization or denial triggers.

    • Do not rely on this list for clinical authorization criteria; seek the full policy or vendor guidance for triggers.
    External precertification review
    Vendor for marked drugsDrugs annotated with † are subject to precertification review by CareCore National, LLC d/b/a eviCore healthcare.
    Documentation noteLimitations, copayments, and restrictions may apply; benefits and cost‑sharing may change on January 1 of each year.
    Scope of reviewPrecertification review by the external vendor applies to the specific drugs identified with the † notation in the drug listing.